Sign in

You're signed outSign in or to get full access.

Kurt McMaken

Director at DuPont de NemoursDuPont de Nemours
Board

About Kurt B. McMaken

Independent director of DuPont de Nemours, Inc. (DD). Age 55; appointed to the Board on February 21, 2025; serves on the Audit Committee and the Nomination & Governance Committee . Background includes CFO of The Brink’s Company since 2022, two decades at Eaton culminating as SVP, Operations Finance & Transformation, and early career at PwC . DuPont’s Board determined he is independent under NYSE and company guidelines; all nominees other than the Executive Chairman (Edward Breen) and CEO (Lori Koch) are independent .

Past Roles

OrganizationRoleTenureCommittees/Impact
The Brink’s CompanyChief Financial Officer2022–present Senior finance leadership for global cash/valuables management
Eaton Corporation plcSVP, Operations Finance & Transformation; prior finance/management roles2001–2022 Led operations finance transformation at a complex global industrial
PricewaterhouseCoopers LLPAudit & Business Advisory Services (early career)Not disclosed Foundation in audit/accounting

External Roles

Company/InstitutionRoleCommittee PositionsTenure
Public company boardsNone disclosed
The Brink’s CompanyCFO (executive role, not a board seat)2022–present

Board Governance

AttributeStatus/Detail
IndependenceIndependent director under NYSE and DuPont guidelines
Board tenureAppointed Feb 21, 2025 (Director since 2025)
CommitteesAudit; Nomination & Governance (member, not chair)
Committee chairsNone (Audit Chair: Sterin; Nom & Gov Chair: Cutler)
Attendance2024: all incumbent directors >75% for Board+committees; McMaken appointed 2025 (2024 N/A)
Lead Independent DirectorAlexander M. Cutler
Executive sessionsNine Board executive sessions in 2024, chaired by Lead Director

Fixed Compensation

ElementAmount/Terms
Annual cash retainer$130,000 (pro-rated for partial-year appointments)
Annual equity retainer$170,000 in RSUs (typically granted at annual meeting; pro-rated for partial-year)
Committee chair feesAudit $35,000; People & Comp $25,000; Other committees $20,000
Lead Director fee$50,000
Initial stock grant (new directors)One-time 1,000 shares upon attending first Board meeting; shares must be held (net after tax) until departure
DeferralDirectors may defer cash fees into stock units; dividend equivalents accrue; held until retirement
Holding requirementDirectors required to hold Company-granted shares until retirement

Performance Compensation

ProgramMetricsNotes
Director equityService-based RSUs onlyNo performance metrics or stock options in current director program; directors received RSUs (e.g., 2,109 RSUs granted June 2024 to incumbents) and are required to hold awards until retirement . DuPont does not currently grant options and has not since FY2022 .

Other Directorships & Interlocks

  • Other current public company boards: None .
  • External executive role: CFO, The Brink’s Company (public issuer) .
  • Outside board service limits: As a public-company executive officer, DuPont limits total public boards to three including employer board; McMaken currently holds one (DuPont), so within guidelines .
  • Related party transactions oversight: Nomination & Governance Committee reviews related person transactions; Board noted routine dealings with companies employing directors/executives were immaterial and ordinary course (each below $1,000,000 or 2% of revenues) .

Expertise & Qualifications

  • Finance and accounting depth from PwC, Eaton, and Brink’s; brings decades of experience managing global, complex businesses .
  • Board skills matrix highlights strong finance/accounting across nominees; McMaken contributes to Audit oversight and governance rigor .

Equity Ownership

HolderCurrent Shares Beneficially OwnedRights to Acquire (through 5/13/2025)TotalOwnership %
Kurt B. McMaken— (less than 1% if any)
  • Note: As of March 14, 2025, McMaken had not reported beneficial ownership; directors are subject to anti-hedging and anti-pledging policies (no hedging, no margin/pledging) .

Governance Assessment

  • Committee assignments and independence: Placement on Audit and Nomination & Governance aligns with his finance background and supports board effectiveness; independence confirmed for all nominees except Executive Chairman and CEO .
  • Ownership alignment: Directors must hold company-granted equity until retirement; new directors receive a 1,000-share initial grant upon first meeting and pro-rated equity retainer, strengthening alignment over time .
  • Compensation structure: Director pay mix is balanced with meaningful equity ($170k RSUs vs $130k cash), favoring long-term alignment; no performance-linked director pay reduces risk of short-termism .
  • Conflicts/related-party exposure: As Brink’s CFO, potential commercial ties would be reviewed under DuPont’s related person policies; Board reported related transactions (where applicable) as immaterial and ordinary course .
  • Process and controls: Robust governance practices include majority voting/resignation policy, executive sessions, annual Board/committee self-evaluations, proxy access, and stockholder engagement .
  • Risk indicators: No Section 16 delinquency noted for McMaken; late filings were disclosed for other executives (Kemp, Weaver) due to administrative errors . Company-wide say-on-pay support was 82.6% in 2024, signaling acceptable compensation governance context .
  • Clawbacks and restrictions: Enhanced clawback policy under NYSE/SEC rules and broader misconduct recoupment; strict anti-hedging/anti-pledging for directors/officers bolster investor alignment .

RED FLAGS: None disclosed specific to McMaken. Short-term ownership is minimal until initial/new director grants are delivered; expected to improve per holding requirements .